Menu
Search
|

Menu

Close
X

Obseva SA OBSV.OQ (NASDAQ Stock Exchange Global Select Market)

12.48 USD
+0.10 (+0.81%)
As of 5:39 PM GMT
chart
Previous Close 12.38
Open 12.25
Volume 7,486
3m Avg Volume 20,249
Today’s High 12.71
Today’s Low 12.25
52 Week High 20.31
52 Week Low 9.05
Shares Outstanding (mil) 29.63
Market Capitalization (mil) 257.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.458
FY17
-2.292
FY16
-1.019
FY15
-0.341
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
2.67
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-66.09
15.05
Return on Equity (TTM)
vs sector
-68.51
16.62

EXECUTIVE LEADERSHIP

Frank Verwiel
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Ernest Loumaye
Chief Executive Officer, Director, Since
Salary: --
Bonus: --
Timothy Adams
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jean-Pierre Gotteland
Chief Scientific Officer, Since 2015
Salary: --
Bonus: --
Fabien de Ladonchamps
Vice President - Finance, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Chemin des Aulx 12
PLAN-LES-OUATES     1228

Phone: +4122.5523840

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).

SPONSORED STORIES